Clinical Trial

A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease

Study acronym: CLEAR-AbKD
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetic, and efficacy of surovatamig administered by subcutaneous injection in adult participants with primary membranous nephropathy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-30.
Trial Details
NCT Number NCT07571746
Lead Sponsor AstraZeneca
Conditions Primary Membranous Nephropathy
Enrollment 43 participants
Start Date 2026-03-28
Primary Completion 2028-04-24 (estimated)
Study Completion 2029-10-15 (estimated)
Updated on ClinicalTrials.gov 2026-08-11